PDS Planning Inc Has $321,000 Stake in Sanofi $SNY

PDS Planning Inc lowered its stake in shares of Sanofi (NASDAQ:SNY) by 10.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 6,642 shares of the company’s stock after selling 783 shares during the period. PDS Planning Inc’s holdings in Sanofi were worth $321,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in SNY. Cardinal Capital Management increased its stake in Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock valued at $3,827,000 after acquiring an additional 199 shares during the period. Perigon Wealth Management LLC grew its stake in Sanofi by 3.1% during the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock worth $367,000 after buying an additional 201 shares during the last quarter. Capital Analysts LLC grew its stake in Sanofi by 14.0% during the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock worth $92,000 after buying an additional 204 shares during the last quarter. Thomasville National Bank grew its stake in Sanofi by 0.3% during the second quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after buying an additional 211 shares during the last quarter. Finally, Hexagon Capital Partners LLC grew its stake in Sanofi by 4.2% during the first quarter. Hexagon Capital Partners LLC now owns 5,959 shares of the company’s stock worth $330,000 after buying an additional 238 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on SNY shares. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Sanofi has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Trading Down 1.5%

Shares of NASDAQ SNY opened at $48.09 on Monday. The company’s 50 day simple moving average is $48.27 and its 200 day simple moving average is $49.75. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The firm has a market capitalization of $118.09 billion, a P/E ratio of 11.56, a P/E/G ratio of 1.17 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the prior year, the company earned $1.73 earnings per share. The company’s quarterly revenue was down 7.0% on a year-over-year basis. On average, analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.